Eiger BioPharmaceuticals, Inc. EIGRQ
8.50
0.00
0.00%
as of 1 Oct
- Market cap
- $2.6M
- P/E
- 0.0×
Follow EIGRQ
Growth Flags
show if company had growth for consecutive years
Target Price Range
Analyst price targets
Free account| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | 321.30 | 183.00 | 223.80 | 281.40 | 136.50 | 150.30 | 28.80 | 6.00 |
Analyst estimates 2024–2026 Powerpack |
Low Price
|
||
| — | — | 774.00 | 435.00 | 540.00 | 474.60 | 453.60 | 404.70 | 300.64 | 89.40 |
High Price
|
|||
| — | — | 20 | 16 | 18 | 24 | 28 | 43 | 56 | 25 |
Employees
|
|||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | 12 | 13 | 16 |
Revenue
|
|||
| — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 93.86% | 86.38% | 99.85% |
Gross Margin
|
|||
| — | — | (47) | (42) | (52) | (70) | (65) | (34) | (97) | (75) |
EBT
|
|||
| — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (278.81%) | (717.54%) | (475.22%) |
EBT Margin
|
|||
| — | — | (47) | (42) | (52) | (70) | (65) | (34) | (97) | (75) |
Net Income
|
|||
| — | — | 0 | 0 | 0 | 0 | 1 | 2 | 1 | (1) |
Depreciation
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.74 | 9.71 | 10.69 |
Revenue/Sh
|
|||
| — | — | (235.43) | (145.95) | (114.71) | (92.49) | (69.37) | (30.03) | (69.67) | (50.78) |
Earnings/Sh
|
|||
| — | — | (189.85) | (132.04) | (93.99) | (83.83) | (67.42) | (63.12) | (59.81) | (50.51) |
Cash Flow/Sh
|
|||
| — | — | (0.29) | 0.54 | (0.31) | (0.63) | (0.28) | (0.20) | (0.24) | (0.16) |
Capex/Sh
|
|||
| — | — | (190.14) | (131.51) | (94.30) | (84.46) | (67.69) | (63.32) | (60.05) | (50.67) |
Free CF/Sh
|
|||
| — | — | 203.61 | 77.50 | 146.68 | 74.43 | 101.40 | 64.05 | 39.85 | (9.80) |
Book Value/Sh
|
|||
| — | — | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
Shares
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | 14.49 | 3.83 | 0.66 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | 2.43 | 0.93 | 0.00 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | 9.80 | (0.53) | 4.24 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | (1.67) | 0.09 | (0.90) |
EV/FCF
|
|||
| — | — | (38) | (38) | (43) | (64) | (63) | (71) | (83) | (75) |
Op' Cash Flow
|
|||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capex
|
|||
| — | — | (38) | (38) | (43) | (64) | (63) | (72) | (83) | (75) |
FCF
|
|||
| — | — | 55 | 35 | 92 | 83 | 121 | 73 | 92 | (15) |
Working Cap'
|
|||
| — | — | 15 | 15 | 26 | 31 | 32 | 32 | 40 | 41 |
Total Debt
|
|||
| — | — | (45) | (27) | (75) | (64) | (97) | (57) | (59) | 16 |
Net Debt
|
|||
| — | — | 41 | 23 | 67 | 56 | 95 | 72 | 55 | (14) |
Sh' Equity
|
|||
| — | — | (142.00%) | (81.93%) | (72.10%) | (67.68%) | (52.31%) | (25.12%) | (78.51%) | (94.31%) |
ROA
|
|||
| — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (312.68%) | 0.00% | (3,674.55%) |
ROIC
|
|||
| — | — | (724.30%) | (134.24%) | (117.58%) | (114.16%) | (85.87%) | (40.51%) | (151.56%) | (367.00%) |
ROE
|
|||
predictions in italic, sparklines do not include predictions
Fiscal years to Dec 2023 · latest quarter Dec 2023
Eiger BioPharmaceuticals, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BIORQ Biora Therapeutics, Inc. | $2.5M | 0.0× | Compare |
| CDT CDT Equity Inc. | $2.4M | 0.0× | Compare |
| MTNB Matinas Biopharma Holdings, Inc. | $2.4M | 0.0× | Compare |
| PPBT Purple Biotech Ltd. Sponsored ADR | $2.4M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ARTL Artelo Biosciences, Inc. | $2.7M | 0.0× | Compare |
| NTBLQ Notable Labs, Ltd. | $2.4M | 0.0× | Compare |
| BPTSY Biophytis SA Sponsored ADR | $2.4M | 0.0× | Compare |
| AFMDQ Affimed N.V. | $2.8M | 0.0× | Compare |
Eiger BioPharmaceuticals, Inc. (EIGRQ) key facts
- Eiger BioPharmaceuticals, Inc. (EIGRQ) is a Biotechnology company in the Healthcare sector.
- Eiger BioPharmaceuticals, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $15.8 million, up 17.0% from fiscal 2022.
- As of October 1, 2024, EIGRQ traded at $8.50, a market capitalization of $2.6 million.
- Return on equity was −367.0% and debt-to-equity -2.84.
Eiger BioPharmaceuticals, Inc. (EIGRQ) Latest News
3 May
Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals
Sentynl Therapeutics acquires global rights to Zokinvy from Eiger BioPharmaceuticals for treatment of progeria. The acquisition of Zokinvy by Sentynl is a significant strategic move that could impact Eiger BioPharmaceuticals' future performance.